FY2025 Earnings Forecast for GENFIT Issued By HC Wainwright

GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) – Equities researchers at HC Wainwright issued their FY2025 earnings estimates for shares of GENFIT in a research report issued to clients and investors on Tuesday, August 19th. HC Wainwright analyst B. Folkes anticipates that the company will earn $0.01 per share for the year. HC Wainwright has a “Buy” rating and a $9.00 price target on the stock. The consensus estimate for GENFIT’s current full-year earnings is $0.95 per share. HC Wainwright also issued estimates for GENFIT’s FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.24) EPS, FY2028 earnings at ($0.90) EPS and FY2029 earnings at ($0.64) EPS.

GENFIT Stock Down 3.6%

NASDAQ:GNFT opened at $4.32 on Thursday. GENFIT has a one year low of $2.55 and a one year high of $6.42. The company has a fifty day moving average price of $3.89 and a 200 day moving average price of $3.85. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.08.

Institutional Investors Weigh In On GENFIT

An institutional investor recently bought a new position in GENFIT stock. Millennium Management LLC purchased a new stake in GENFIT S.A. Unsponsored ADR (NASDAQ:GNFT) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 166,375 shares of the company’s stock, valued at approximately $611,000. Millennium Management LLC owned 0.33% of GENFIT at the end of the most recent reporting period. Institutional investors and hedge funds own 2.24% of the company’s stock.

GENFIT Company Profile

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.